Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.
Abbott's landmark LIFE-BTK randomized clinical trial met its primary safety and effectiveness endpoints, demonstrating that Esprit BTK offers significant advancements in opening and keeping blocked arteries below-the-knee open compared to the standard of care, balloon angioplasty
The Peptide Receptor Radionuclide Therapy (PRRT) Industry is on a trajectory of exceptional growth, with projections indicating a worth of US$ 591.83 million in 2023 and a substantial leap towards US$ 1,300 million by 2033. This robust expansion is driven by a promising Compound Annual Growth Rate (CAGR) of 8.2% exp.